Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have completed 52 weeks of treatment of the double blind placebo-controlled phase of ALS-TAL-201.~* Women must be postmenopausal, surgically sterile, or using adequate birth control methods.~* Patients must be willing and able to give written informed consent prior to performing any open-label study procedures.~Exclusion Criteria:~* Patients with ECG signs of Brugada syndrome and/ or complete or incomplete Right Bundle Branch Block~* Patients using any of the following:~  * Chronic use of lithium carbonate~ * Chronic use of mecasermin (rhIGF-1)~ * Chronic use of minocycline~ * Chronic use of more than 600mg/day coenzyme Q10~ * Chronic use of any marketed drug, if its use was not clearly indicated for any underlying medical condition other than ALS (symptomatic drugs for ALS and supplements allowed)~* Patients participating in any other investigational drug study and use of any other investigational drug~* Patients taking drugs that may interact with Talampanel~* Females who are pregnant or nursing.~* Females of child-bearing potential who do not practice medically acceptable methods of contraception.~* Any condition of the patient which the investigator feels may interfere with participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Talampanel (Type: EXPERIMENTAL): Talampanel 50mg tid

Based on this trial design, predict the completion outcome and termination type (if applicable).